COMMUNIQUÉS West-GlobeNewswire

Supernus Announces Second Quarter 2024 Financial Results

06/08/2024 - 22:06

Net sales of Qelbree ® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. [...]

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

06/08/2024 - 22:05

Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration [...]

Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements

06/08/2024 - 22:05

DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, [...]

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

06/08/2024 - 22:05

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused [...]

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results

06/08/2024 - 22:05

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with [...]

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024

06/08/2024 - 22:05

INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024 Soumission réglementaire auprès de la complétée, l'approbation aux États-Unis est [...]

Nanox to Report Second Quarter and Financial Results on August 20, 2024

06/08/2024 - 22:05

PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

06/08/2024 - 22:05

- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic [...]

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

06/08/2024 - 22:05

ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

06/08/2024 - 22:05

- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed equity offering with [...]

Treace Medical Concepts Reports Second Quarter 2024 Financial Results

06/08/2024 - 22:05

PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

06/08/2024 - 22:05

Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen customer base Amir Avniel, Beyond Air Board member and Chief Business [...]

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06/08/2024 - 22:05

WALTHAM, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity [...]

BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

06/08/2024 - 22:05

MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today [...]

OraSure Reports Q2 ’24 Revenue of $54.3 Million

06/08/2024 - 22:05

Q2 GAAP EPS of $(0.01) ; Q2 Non-GAAP EPS of $0.07 OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification Strong momentum with Syphilis Health Check™ launch Expanding Sample Management applications [...]

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

06/08/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

06/08/2024 - 22:05

-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 [...]

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06/08/2024 - 22:05

Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75% Focus R&D investment [...]

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

06/08/2024 - 22:05

Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed [...]